Mixed Testosterone Ester Blend (Sustanon-type)
A generic multi-ester testosterone blend modelled on the Sustanon concept, combining short, medium and long esters (typically propionate, phenylpropionate, isocaproate and decanoate) in one oil solution. The staggered esters give a fast onset from the short fractions and a sustained tail from the long ones, allowing less frequent dosing than a single short ester. Widely counterfeited, so exact ratios vary between products.
01 Overview
The original Sustanon 250 formulation was designed for hormone replacement so that a single monthly injection could maintain physiological testosterone. In practice the blend does not deliver truly stable levels and dedicated users inject far more frequently. Underground blends copy the multi-ester idea but with inconsistent ratios, total concentrations and carrier oils.
Pharmacologically the blend is simply testosterone: once each ester hydrolyses, the active hormone is identical. The clinical difference is only in release timing. Because the short propionate fraction begins acting within a day while the decanoate tail persists for weeks, injection frequency and blood-level smoothness are the main practical considerations.
02 Mechanism
Each ester is cleaved by esterases at a different rate to release testosterone, which activates the androgen receptor to drive protein synthesis and aromatises to estradiol.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| TRT | 100–200 mg/wk | IM | Split every 3-4 days to blunt peaks despite label claims of monthly dosing. |
| Enhancement | 300–600 mg/wk | IM | Typically divided into two or more weekly injections. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Increased lean mass and strengthTestosterone's anabolic effect is robust and well quantified. | Dose-dependent, +several kg | Clinical | |
| Fast onset with sustained tailThe short esters give early effect while long esters extend duration between injections. | Onset within 24-48 h | Observational | |
| Improved libido and moodRestores androgen-dependent wellbeing. | Normalisation in hypogonadism | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Estrogenic side effectsGynecomastia, water retention and raised blood pressure from aromatisation. | Moderate | Common at higher doses | Clinical | |
| HPTA suppressionTesticular atrophy and impaired fertility from feedback suppression. | Severe | Universal | Clinical | |
| PolycythemiaTestosterone raises hematocrit, increasing blood viscosity and thrombotic risk. | Moderate | Common with chronic use | Clinical |